Agenus, based in Berkeley, CA, is a biotechnology company focused on harnessing the power of the immune system to develop curative therapies for cancer patients. Their innovative approach includes developing next-generation antibodies like botensilimab to target cold tumors and enhance the efficacy and tolerability of immunotherapy.
With a strong pipeline of immuno-oncology therapeutics and strategic partnerships with industry leaders, Agenus aims to expand the patient population benefiting from immunotherapy through combination approaches and cutting-edge research in antibody therapeutics, adoptive cell therapies, adjuvants, and vaccines.
Generated from the website